Senores Pharmaceuticals Limited share price
NSE: SENORES · ISIN INE0RB801010
Key numbers
- Market cap
- ₹ 6,241 Cr
- Current price
- ₹ 1,355.20
- 52-week high / low
- ₹ 1,599 / 662
- Stock P/E
- 47.8
- Book value
- ₹ 235.1
- Dividend yield
- 0.00%
- ROCE
- 15.4%
- ROE
- 13.4%
- Debt to equity
- 0.37
- Sales growth (3 yrs)
- 159.1%
- Profit growth (3 yrs)
- 139.2%
- 1-year return
- 92.7%
About Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, nutritional supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 133 | 153 | 165 | 175 | 180 |
| Operating profit | 29 | 50 | 54 | 47 | 54 |
| Net profit | 20 | 32 | 32 | 32 | 31 |
| EPS (₹) | 4.60 | 6.54 | 7.29 | 7.96 | 6.61 |
Concall summary (2026-08-03)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Based on the current business outlook and execution visibility, we expect the revenue growth of approximately 30% to 40% and PAT growth for about 50% to 60% for FY27, with a similar growth trajectory expected to continue thereafter.
- Speaking about segmental performance, our regulated market business delivered strong performance in Q1 FY27, registering a robust 36% (Actual growth is 42%.
Growth & demand
- Mistakenly mentioned as 36% on the call.) year-over-year revenue growth.
- Emerging markets revenue grew by around 30% in Q1 FY27.
Margins & costs
- Consolidated EBITDA for Q1 of FY27 stood at INR54 crores, growing by a robust 87% on a Y-o-Y basis.
- EBITDA margins stood at almost 30%, improving by 810 bps Y-o-Y.
Capex & expansion
- This was driven by the continued expansion of our product portfolio, differentiated sales and distribution channels.
- So, we are easily operating at about 80%- 90% of our capacity in terms of production capacity, not from a revenue standpoint because there's lot of filing and qualification is happening.
Balance sheet & cash
- On a consolidated basis, we remain focused on driving strong cash flow generation alongside profitable growth.
- Our operating cash flows have continued to improve steadily reflecting the quality of our earnings and strength of our operating model.
Peers in Drug Manufacturers - General
Data for information only, not investment advice. Prices end of day.